

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Proposed Single Technology Appraisal (STA)

**Olaparib for the maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer with BRCA 1 or 2 mutations following response to prior platinum-based chemotherapy**

#### Provisional matrix of consultees and commentators

| Consultees  | Commentators (no right to submit or appeal)  |
|---|--|
| <p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• AstraZeneca (olaparib)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer 52</li> <li>• Equalities National Council</li> <li>• HAWC</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie Cancer Care</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Ovacome</li> <li>• Ovarian Cancer Action</li> <li>• Rarer Cancers Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Target Ovarian Cancer</li> <li>• Tenovus</li> <li>• Wellbeing of Women</li> <li>• Women's Health Concern</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• British Geriatrics Society</li> </ul> | <p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Health Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Gynaecological Cancer Group</li> <li>• Eve appeal</li> <li>• Health Research Authority</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> </ul> |

National Institute for Health and Care Excellence

Provisional matrix for the proposed technology appraisal olaparib for the maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer with BRCA 1 or 2 mutations following response to prior platinum-based chemotherapy

Issue date: March 2014

Page 1 of 3

| <b>Consultees</b>   | <b>Commentators (no right to submit or appeal)</b>   |
|---|--|
| <ul style="list-style-type: none"> <li>• British Gynaecological Cancer Society</li> <li>• British Institute of Radiology</li> <li>• British Psychosocial Oncology Society</li> <li>• British Society of Urogynaecology</li> <li>• Cancer Network Pharmacists Forum</li> <li>• Cancer Research UK</li> <li>• National Forum of Gynaecological Oncology Nurses</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Obstetricians &amp; Gynaecologists</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• UK Health Forum</li> <li>• United Kingdom Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS Bristol CCG</li> <li>• NHS Dartford, Gravesham and Swanley CCG</li> <li>• NHS England</li> <li>• Welsh Government</li> </ul> | <ul style="list-style-type: none"> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> <li>• Ovarian &amp; Prostate Cancer Research Trust</li> <li>• Research Institute for the Care of Older People</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• Evidence Review Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Cancer</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales NHS Trust</li> </ul> |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS***

National Institute for Health and Care Excellence

Provisional matrix for the proposed technology appraisal olaparib for the maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer with BRCA 1 or 2 mutations following response to prior platinum-based chemotherapy

Issue date: March 2014

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.